Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

NURO

Neurometrix Inc

Dec 12 • 04:00PM ET

3.90

Dollar change -0.10
Percentage change -2.50	%

Healthcare • Medical Devices • USA • NASD

Peers: NVCR SYK ABT DXCM IART BSX PODD TNDM ZBH SENS

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.24	Insider Own	28.69%	Shs Outstand	2.03M	Perf Week	-9.51%
Market Cap	7.97M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.46M	Perf Month	5.98%
Income	-7.68M	PEG	-	EPS next Q	-	Inst Own	3.01%	Short Float	2.13%	Perf Quarter	-2.50%
Sales	3.77M	P/S	2.11	EPS this Y	-	Inst Trans	79.87%	Short Ratio	1.77	Perf Half Y	4.84%
Book/sh	7.86	P/B	0.50	EPS next Y	-	ROA	-39.90%	Short Interest	0.03M	Perf Year	11.75%
Cash/sh	7.26	P/C	0.54	EPS next 5Y	-	ROE	-42.78%	52W Range	2.66 - 4.73	Perf YTD	8.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-48.03%	52W High	-17.55%	Beta	2.21
Dividend TTM	-	Quick Ratio	12.70	Sales past 5Y	-15.89%	Gross Margin	57.56%	52W Low	46.62%	ATR (14)	0.27
Dividend Ex-Date	Mar 28, 2007	Current Ratio	13.88	EPS Y/Y TTM	23.95%	Oper. Margin	-230.42%	RSI (14)	43.98	Volatility	6.37% 7.22%
Employees	26	Debt/Eq	0.01	Sales Y/Y TTM	-41.41%	Profit Margin	-203.71%	Recom	1.00	Target Price	50.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	55.12%	Payout	-	Rel Volume	0.15	Prev Close	4.00
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-51.19%	Earnings	Aug 06 BMO	Avg Volume	17.55K	Price	3.90
SMA20	-5.12%	SMA50	-4.44%	SMA200	-0.21%	Trades		Volume	2,644	Change	-2.50%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-17	Reiterated	H.C. Wainwright	Buy	$10 → $3
Jun-28-16	Initiated	Rodman & Renshaw	Buy	$4.50
Sep-11-15	Initiated	Maxim Group	Buy	$2
Feb-27-12	Initiated	Dawson James	Buy	$3

Nov-05-24 07:00AM	NeuroMetrix Reports Q3 2024 Business Highlights (GlobeNewswire) -6.82%
Aug-13-24 02:47PM	NeuroMetrix Reiterates its Review of Strategic Alternatives (GlobeNewswire)
Aug-06-24 07:00AM	NeuroMetrix Reports Q2 2024 Business Highlights and Update on Review of Strategic Options (GlobeNewswire) -10.73%
Jul-31-24 02:03PM	NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call (GlobeNewswire)
May-15-24 09:54PM	NURO Stock Earnings: NeuroMetrix Reported Results for Q1 2024 (InvestorPlace)
04:00PM	Loading…
04:00PM	NeuroMetrix Reports Q1 2024 Business Highlights (GlobeNewswire)
Apr-19-24 08:00AM	NeuroMetrix Announces Steps Taken to Enhance Shareholder Value (GlobeNewswire) +18.63%
Mar-14-24 09:00AM	NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy (GlobeNewswire)
Mar-13-24 09:00AM	NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell Fibromyalgia (GlobeNewswire)
Mar-12-24 08:00AM	Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired (ACCESSWIRE)
Mar-08-24 11:15AM	RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc. (ACCESSWIRE)
Mar-04-24 08:00AM	Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc. (ACCESSWIRE) -5.97%
Feb-23-24 11:23AM	NeuroMetrix, Inc. (NASDAQ:NURO) Q4 2023 Earnings Call Transcript (Insider Monkey) +5.78%
Feb-22-24 10:28PM	Q4 2023 NeuroMetrix Inc Earnings Call (Thomson Reuters StreetEvents) -7.26%
07:00AM	NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights (GlobeNewswire)
09:00AM	Loading…
Feb-15-24 09:00AM	NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call (GlobeNewswire) +9.57%
Feb-13-24 09:00AM	NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value (GlobeNewswire) -8.55%
Jan-10-24 07:00AM	Presenting on Emerging Growth Conference 66 Day 2 on January 11 Register to Stream (GlobeNewswire)
Jan-09-24 07:00AM	Presenting on the Emerging Growth Conference 66 Day 1 on January 10 Register Now (GlobeNewswire)
Jan-08-24 09:43AM	NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024 (GlobeNewswire)
Dec-12-23 09:00AM	NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell in Post-Acute COVID-19 Syndrome (Long COVID) (GlobeNewswire)
Dec-05-23 09:00AM	NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN) (GlobeNewswire)
Nov-20-23 09:00AM	NeuroMetrix Announces One-for-Eight Reverse Stock Split (GlobeNewswire)
Nov-01-23 07:00AM	Presenting on the Emerging Growth Conference 64 Day 2 on November 2 Register Now (GlobeNewswire)
Oct-31-23 07:00AM	Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now (GlobeNewswire) -8.82%
Oct-30-23 09:00AM	NeuroMetrix to Present at the Emerging Growth Conference on November 1, 2023 (GlobeNewswire)
Oct-28-23 09:43AM	NeuroMetrix, Inc. (NASDAQ:NURO) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-26-23 11:45PM	Q3 2023 NeuroMetrix Inc Earnings Call (Thomson Reuters StreetEvents) -19.10%
07:00AM	NeuroMetrix Reports Q3 2023 Business Highlights (GlobeNewswire)
Oct-23-23 11:13AM	NeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference Call (GlobeNewswire)
07:00AM	Loading…
Oct-04-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now (GlobeNewswire)
Oct-03-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now (GlobeNewswire) -6.57%
Oct-02-23 09:00AM	NeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia (GlobeNewswire)
Sep-28-23 12:19PM	NeuroMetrix to Present at the Emerging Growth Conference on October 4, 2023 (GlobeNewswire) +8.90%
Aug-30-23 09:00AM	NeuroMetrix to Present at the Emerging Growth Conference on September 6, 2023 (GlobeNewswire)
Aug-28-23 11:42AM	Is NeuroMetrix (NURO) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap (GuruFocus.com) +5.93%
Jul-27-23 09:04PM	Q2 2023 NeuroMetrix Inc Earnings Call (Thomson Reuters StreetEvents) -6.97%
07:00AM	NeuroMetrix Reports Q2 2023 Business Highlights (GlobeNewswire)
Jul-20-23 01:00PM	NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference Call (GlobeNewswire)
Jul-11-23 09:00AM	NeuroMetrix Announces Sales Force Expansion for Quell Fibromyalgia (GlobeNewswire)
Jun-28-23 09:00AM	Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes Patients (GlobeNewswire) +5.44%
Jun-07-23 09:00AM	Diabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical Study (GlobeNewswire)
May-31-23 09:00AM	Quell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN) (GlobeNewswire)
May-03-23 09:17PM	Q1 2023 NeuroMetrix Inc Earnings Call (Thomson Reuters StreetEvents) -23.74%
07:00AM	NeuroMetrix Reports Q1 2023 Financial Results (GlobeNewswire)
Apr-28-23 09:21AM	NeuroMetrix, Inc. Announces Date for First Quarter 2023 Financial Results Conference Call (GlobeNewswire)
Mar-21-23 09:00AM	NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting (GlobeNewswire)
Feb-25-23 07:36AM	NeuroMetrix Full Year 2022 Earnings: US$0.62 loss per share (vs US$0.45 loss in FY 2021) (Simply Wall St.)
Feb-23-23 07:00AM	NeuroMetrix Reports Q4 and Full Year 2022 Financial Results (GlobeNewswire)
Feb-16-23 02:58PM	NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference Call (GlobeNewswire)
Jan-23-23 09:00AM	NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy (GlobeNewswire) +5.03%
Nov-08-22 09:00AM	NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting (GlobeNewswire) -6.70%
Nov-03-22 09:00AM	NeuroMetrix Announces Strategic Launch of Quell Fibromyalgia (GlobeNewswire) -10.19%
Oct-20-22 07:00AM	NeuroMetrix Reports Q3 2022 Financial Results (GlobeNewswire) -10.43%
Oct-12-22 03:47PM	NeuroMetrix, Inc. Announces Date for Third Quarter 2022 Financial Results Conference Call (GlobeNewswire)
Sep-25-22 08:26AM	Companies Like NeuroMetrix (NASDAQ:NURO) Are In A Position To Invest In Growth (Simply Wall St.)
Sep-01-22 09:00AM	NeuroMetrix Names Jonathan Breck Harmel as National Director of Sales for its Emerging Prescription Neurotherapeutics Business (GlobeNewswire)
Jul-21-22 07:00AM	NeuroMetrix Reports Q2 2022 Financial Results (GlobeNewswire)
Jul-14-22 11:32AM	NeuroMetrix, Inc. Announces Date for Second Quarter 2022 Financial Results Conference Call (GlobeNewswire)
Jun-28-22 09:00AM	NeuroMetrix Appoints Brad Fluegel to its Board of Directors (GlobeNewswire)
May-19-22 09:00AM	NeuroMetrix Reports that Quell® Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia (GlobeNewswire) +76.28%
Apr-26-22 07:00AM	NeuroMetrix Reports Q1 2022 Financial Results (GlobeNewswire) -11.20%
Apr-19-22 09:00AM	NeuroMetrix, Inc. Announces Date for First Quarter 2022 Financial Results Conference Call (GlobeNewswire)
Apr-18-22 06:35AM	Companies Like NeuroMetrix (NASDAQ:NURO) Are In A Position To Invest In Growth (Simply Wall St.)
Feb-24-22 02:21PM	NeuroMetrix's Quell Neuromodulator Will Be Tested In Long COVID-19 Syndrome (Benzinga)
09:00AM	NeuroMetrix Reports that Quell® Wearable Neuromodulator to be Evaluated in Post-Acute COVID-19 Syndrome (GlobeNewswire)
Jan-27-22 07:00AM	NeuroMetrix Reports Q4 and Full Year 2021 Financial Results (GlobeNewswire) -7.47%
Jan-20-22 12:10PM	NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2021 Financial Results Conference Call (GlobeNewswire)
Jan-18-22 11:54AM	NURO Stock: Why NeuroMetrix Investors Are Feeling No Pain Today (InvestorPlace) +29.47%
09:00AM	NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology (GlobeNewswire)
08:28AM	NeuroMetrix Up 31.5% on FDA Breakthrough Device Designation (Investing.com)
Jan-10-22 09:00AM	NeuroMetrix Names Strategic Growth Executive, Brandi Damkier, as Vice President, Clinical Partnerships (GlobeNewswire) +7.66%
Jan-05-22 09:00AM	NeuroMetrix to Present at H.C. Wainwright BioConnect Conference 2022 (GlobeNewswire)
Oct-21-21 07:00AM	NeuroMetrix Reports Q3 2021 Financial Results (GlobeNewswire) -8.24%
Oct-20-21 09:00AM	NeuroMetrix Names Strategic Growth Executive, Susan M. Bell, RN, BN, as Senior Vice President of Population Health & Value Based Care (GlobeNewswire)
08:50AM	Those who invested in NeuroMetrix (NASDAQ:NURO) a year ago are up 453% (Simply Wall St.)
Oct-14-21 09:00AM	NeuroMetrix, Inc. Announces Date for Third Quarter 2021 Financial Results Conference Call (GlobeNewswire)
Oct-07-21 12:01PM	28 Stocks Moving In Thursday's Mid-Day Session (Benzinga) +11.37%
07:01AM	18 Stocks Moving in Thursday's Pre-Market Session (Benzinga)
Oct-06-21 06:42PM	NeuroMetrix Announces Submission of FDA De Novo Request for Treatment of Fibromyalgia Symptoms with the Quell® Wearable Neuromodulation Device (GlobeNewswire) -8.10%
Oct-05-21 09:00AM	NeuroMetrix Announces Participation in the Center to Stream Healthcare In Place (C2SHIP) as an Industry Partner (GlobeNewswire)
Aug-30-21 07:05AM	28 Stocks Moving in Monday's Pre-Market Session (Benzinga) -15.93%
Aug-27-21 12:58PM	What's Going On With NeuroMetrix Shares Today? (Benzinga) +65.60%
12:04PM	35 Stocks Moving In Friday's Mid-Day Session (Benzinga)
11:09AM	NURO Stock: 9 Things to Know About NeuroMetrix as Meme Stock Investors Send Shares Soaring (InvestorPlace)
07:08AM	22 Stocks Moving in Friday's Pre-Market Session (Benzinga)
04:44AM	Support.com and NeuroMetrix Stocks Soar on Meme Boost (TheStreet.com)
Aug-13-21 03:24PM	Buy NeuroMetrix Stock If You Enjoy a Suckers Bet (InvestorPlace) -11.53%
Jul-26-21 09:00AM	NeuroMetrix Announces Peer-Reviewed Publication of a Randomized Controlled Trial of its Wearable Neurostimulation Technology for Treatment of Fibromyalgia (GlobeNewswire) -13.45%
Jul-22-21 07:00AM	NeuroMetrix Reports Q2 2021 Financial Results (GlobeNewswire) +18.89%
05:46AM	Companies Like NeuroMetrix (NASDAQ:NURO) Can Afford To Invest In Growth (Simply Wall St.)
Jul-21-21 04:35AM	Premarket Movers Wednesday: Chembio, NeuroMetrix, Johnson & Johnson (TheStreet.com) +107.17%
Jul-20-21 02:54PM	NeuroMetrix stock more than triples on massive volume after fibromyalgia treatment gets FDA boost (MarketWatch) +207.98%
01:37PM	Shares of NeuroMetrix more than double after positive FDA news (Fortune)
11:14AM	NeuroMetrix Soars on FDA 'Breakthrough Status' for Fibromyalgia Device (TheStreet.com)
11:04AM	NeuroMetrix Stock Surges As Its Nerve Stimulator Scores FDA Breakthrough Designation For Fibromyalgia (Benzinga)
09:00AM	NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Fibromyalgia with its Wearable Neurostimulation Technology (GlobeNewswire)
Jul-15-21 09:00AM	NeuroMetrix, Inc. Announces Date for Second Quarter 2021 Financial Results Conference Call (GlobeNewswire)
Jun-15-21 09:00AM	NeuroMetrix Reports that Quell® Technology is to be Evaluated for Neuromyelitis Optica Spectrum Disorder (NMOSD) in a Randomized Controlled Trial (GlobeNewswire)
Jun-09-21 11:20AM	NeuroMetrix's Nerve Stimulator Shows Mixed Outcomes In Fibromyalgia Trial (Benzinga)

NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. Its products include DPNCheck, Quell, and ADVANCE system. It also focuses on the sale of medical equipment and consumables. The company was founded by Shai N. Gozani in June 1996 and is headquartered in Woburn, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HIGGINS THOMAS T	Senior Vice President, CFO	Nov 02 '24	Option Exercise	4.00	498	1,992	10,663	Nov 05 10:32 AM
Gozani Shai	President & CEO	Nov 02 '24	Option Exercise	4.00	636	2,544	13,854	Nov 05 10:30 AM
HIGGINS THOMAS T	Senior Vice President, CFO	Oct 01 '24	Option Exercise	4.18	469	1,960	10,213	Oct 02 04:21 PM
Gozani Shai	President & CEO	Oct 01 '24	Option Exercise	4.18	625	2,612	13,260	Oct 02 04:20 PM
HIGGINS THOMAS T	Senior Vice President, CFO	Aug 02 '24	Option Exercise	3.46	498	1,723	9,790	Sep 26 05:12 PM
Gozani Shai	President & CEO	Aug 02 '24	Option Exercise	3.46	636	2,201	12,713	Sep 26 05:11 PM
HIGGINS THOMAS T	Senior Vice President, CFO	Jul 01 '24	Option Exercise	3.64	469	1,707	9,331	Sep 26 04:58 PM
Gozani Shai	President & CEO	Jul 01 '24	Option Exercise	3.64	625	2,275	12,154	Sep 26 04:57 PM
HIGGINS THOMAS T	Senior Vice President, CFO	May 02 '24	Option Exercise	4.47	498	2,226	8,946	May 07 04:44 PM
Gozani Shai	President & CEO	May 02 '24	Option Exercise	4.47	636	2,843	11,608	May 07 04:43 PM
Fluegel Bradley M	Director	Apr 30 '24	Option Exercise	4.37	5,396	23,581	8,634	May 02 04:02 PM
Van Avermaete David	Director	Apr 30 '24	Option Exercise	4.37	5,396	23,581	7,601	May 02 04:01 PM
Goodman David	Director	Apr 30 '24	Option Exercise	4.37	5,396	23,581	7,602	May 02 04:01 PM
KATZ NANCY E	Director	Apr 30 '24	Option Exercise	4.37	5,396	23,581	7,602	May 02 04:00 PM
HIGGINS THOMAS T	Senior Vice President, CFO	Apr 01 '24	Option Exercise	4.06	469	1,904	8,522	Apr 04 03:39 PM
Gozani Shai	President & CEO	Apr 01 '24	Option Exercise	4.06	625	2,537	11,049	Apr 04 03:39 PM
HIGGINS THOMAS T	Senior Vice President, CFO	Feb 02 '24	Option Exercise	3.03	498	1,509	8,123	Mar 06 05:23 PM
Gozani Shai	President & CEO	Feb 02 '24	Option Exercise	3.03	636	1,927	10,518	Mar 06 05:23 PM
HIGGINS THOMAS T	Senior Vice President, CFO	Jan 01 '24	Option Exercise	3.60	469	1,688	7,693	Mar 06 05:22 PM
Gozani Shai	President & CEO	Jan 01 '24	Option Exercise	3.60	625	2,250	9,956	Mar 06 05:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NURO

Neurometrix Inc

Upgrade your FINVIZ experience